N4 Pharma PLC Change in Director Details (7072K)

TIDMN4P

RNS Number : 7072K

N4 Pharma PLC

11 July 2017

11 July 2017

N4 Pharma Plc

("N4 Pharma" or the "Company")

Change in Director Details

In accordance with Rule 17 and paragraph (g) of Schedule Two of the AIM Rules for Companies, the Company announces that it was on 10 July 2017 notified by Paul Titley, an Executive Director of the Company, that Critical Pharmaceuticals Limited ("Critical"), a company of which he is a Non-Executive Director, has been placed into creditors' voluntary liquidation. Mr Titley's authority as a director of Critical ceased on appointment of the liquidator.

Enquiries:

 
 N4 Pharma               Via Alma PR 
  CEO, Nigel Theobald 
 Stockdale Securities    Tel: [phone] 
  Tom Griffiths           6100 
 Beaufort Securities     Tel: [phone] 
  Elliot Hance            8300 
 Alma PR                 Tel: [phone] 
  Josh Royston            1979 
  Robyn Fisher            Tel: [phone] 
                          6191 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance. Its shares were admitted to trading on AIM on 3 May 2017.

N4 Pharma's reformulation work falls under two divisions:

-- generic, already commercialised, drugs; and

-- delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAEANXFFANXEEF

(END) Dow Jones Newswires

July 11, 2017 05:31 ET (09:31 GMT)